Literature DB >> 16053701

Chaperone proteins and brain tumors: potential targets and possible therapeutics.

Michael W Graner1, Darell D Bigner.   

Abstract

Chaperone proteins are most notable for the proteo- and cyotoprotective capacities they afford during cellular stress. Under conditions of cellular normalcy, chaperones still play integral roles in the folding of nascent polypeptides into functional entities, in assisting in intracellular/intraorganellar transport, in assembly and maintenance of multi-subunit protein complexes, and in aiding and abetting the degradation of senescent proteins. Tumors frequently have relatively enhanced needs for chaperone number and activity because of the stresses of rapid proliferation, increased metabolism, and overall genetic instability. Thus, it may be possible to take advantage of this reliance that tumor cells have on chaperones by pharmacologic and biologic means. Certain chaperones are abundant in the brain, which implies important roles for them. While it is presumed that the requirements of brain tumors for chaperone proteins are similar to those of any other cell type, tumor or otherwise, very little inquiry has been directed at the possibility of using chaperone proteins as therapeutic targets or even as therapeutic agents against central nervous system malignancies. This review highlights some of the research on the functions of chaperone proteins, on what can be done to modify those functions, and on the physiological responses that tumors and organisms can have to chaperone-targeted or chaperone-based therapies. In particular, this review will also underscore areas of research where brain tumors have been part of the field, although in general those instances are few and far between. This relative dearth of research devoted to chaperone protein targets and therapeutics in brain tumors reveals much untrodden turf to explore for potential treatments of these dreadfully refractive diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16053701      PMCID: PMC1871914          DOI: 10.1215/S1152851704001188

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  198 in total

Review 1.  Cell surface expression of heat shock proteins and the immune response.

Authors:  G Multhoff; L E Hightower
Journal:  Cell Stress Chaperones       Date:  1996-09       Impact factor: 3.667

2.  Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone.

Authors:  C Prodromou; S M Roe; R O'Brien; J E Ladbury; P W Piper; L H Pearl
Journal:  Cell       Date:  1997-07-11       Impact factor: 41.582

Review 3.  Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

Authors:  A D Cox; C J Der
Journal:  Biochim Biophys Acta       Date:  1997-08-08

4.  A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.

Authors:  D M Ashley; J H Sampson; G E Archer; S K Batra; D D Bigner; L P Hale
Journal:  J Neuroimmunol       Date:  1997-09       Impact factor: 3.478

5.  A lymphocyte cell surface heat shock protein homologous to the endoplasmic reticulum chaperone, immunoglobulin heavy chain binding protein BIP.

Authors:  C L Berger; Z Dong; D Hanlon; E Bisaccia; R L Edelson
Journal:  Int J Cancer       Date:  1997-06-11       Impact factor: 7.396

6.  The constitutive heat shock protein-70 is required for optimal expression of myelin basic protein during differentiation of oligodendrocytes.

Authors:  D A Aquino; D Peng; C Lopez; M Farooq
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

7.  Expression analysis of mortalin, a unique member of the Hsp70 family of proteins, in rat tissues.

Authors:  S C Kaul; M Matsui; S Takano; T Sugihara; Y Mitsui; R Wadhwa
Journal:  Exp Cell Res       Date:  1997-04-10       Impact factor: 3.905

8.  Elevated levels of mortalin expression in human brain tumors.

Authors:  S Takano; R Wadhwa; Y Yoshii; T Nose; S C Kaul; Y Mitsui
Journal:  Exp Cell Res       Date:  1997-11-25       Impact factor: 3.905

9.  Geldanamycin-induced destabilization of Raf-1 involves the proteasome.

Authors:  T W Schulte; W G An; L M Neckers
Journal:  Biochem Biophys Res Commun       Date:  1997-10-29       Impact factor: 3.575

10.  Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity.

Authors:  N E Blachere; Z Li; R Y Chandawarkar; R Suto; N S Jaikaria; S Basu; H Udono; P K Srivastava
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

View more
  23 in total

1.  Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma.

Authors:  Yashu Liu; Jintang He; Xaiolei Xie; Gang Su; Seagal Teitz-Tennenbaum; Michael S Sabel; David M Lubman
Journal:  J Proteome Res       Date:  2010-10-20       Impact factor: 4.466

2.  Downregulated expression of HSP27 in human low-grade glioma tissues discovered by a quantitative proteomic analysis.

Authors:  Guobo Shen; Shufang Liang; Zhizhong Xu; Liangxue Zhou; Shiyin Xiao; Xiangying Xia; Ronghui Li; Ying Liao; Chao You; Yuquan Wei
Journal:  Proteome Sci       Date:  2010-03-26       Impact factor: 2.480

Review 3.  Vaccine strategies for glioblastoma: progress and future directions.

Authors:  Christopher Jackson; Jacob Ruzevick; Henry Brem; Michael Lim
Journal:  Immunotherapy       Date:  2013-02       Impact factor: 4.196

4.  Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas.

Authors:  Gisela N Castro; Niubys Cayado-Gutiérrez; Vera L Moncalero; Patricia Lima; Rodolfo Lucero De Angelis; Victor Chávez; F Darío Cuello-Carrión; Daniel R Ciocca
Journal:  Cell Stress Chaperones       Date:  2012-07-18       Impact factor: 3.667

5.  HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.

Authors:  Arin N Graner; Justin E Hellwinkel; Alex M Lencioni; Helen J Madsen; Tessa A Harland; Paul Marchando; Ger J Nguyen; Mary Wang; Laura M Russell; Lynne T Bemis; Thomas J Anchordoquy; Michael W Graner
Journal:  Int J Hyperthermia       Date:  2016-12-20       Impact factor: 3.914

Review 6.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

7.  Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex.

Authors:  Christina B Clark; Madhavi J Rane; Delphine El Mehdi; Cynthia J Miller; Leroy R Sachleben; Evelyne Gozal
Journal:  Free Radic Biol Med       Date:  2009-08-21       Impact factor: 7.376

8.  Heat-shock protein vaccines as active immunotherapy against human gliomas.

Authors:  Isaac Yang; Seunggu Han; Andrew T Parsa
Journal:  Expert Rev Anticancer Ther       Date:  2009-11       Impact factor: 4.512

9.  Proteomic and immunologic analyses of brain tumor exosomes.

Authors:  Michael W Graner; Oscar Alzate; Angelika M Dechkovskaia; Jack D Keene; John H Sampson; Duane A Mitchell; Darell D Bigner
Journal:  FASEB J       Date:  2008-12-24       Impact factor: 5.191

10.  Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces.

Authors:  Michael W Graner; Deborah A Raynes; Darell D Bigner; Vince Guerriero
Journal:  Cancer Sci       Date:  2009-07-01       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.